ATE297987T1 - Bedingte immortalisierung von zellen - Google Patents

Bedingte immortalisierung von zellen

Info

Publication number
ATE297987T1
ATE297987T1 AT00960846T AT00960846T ATE297987T1 AT E297987 T1 ATE297987 T1 AT E297987T1 AT 00960846 T AT00960846 T AT 00960846T AT 00960846 T AT00960846 T AT 00960846T AT E297987 T1 ATE297987 T1 AT E297987T1
Authority
AT
Austria
Prior art keywords
cells
conditional immortalization
recombinant
conditionally
therapy
Prior art date
Application number
AT00960846T
Other languages
English (en)
Inventor
Parmjit Jat
Original Assignee
Reneuron Ltd
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneuron Ltd, Ludwig Inst Cancer Res filed Critical Reneuron Ltd
Application granted granted Critical
Publication of ATE297987T1 publication Critical patent/ATE297987T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00960846T 1999-09-17 2000-09-18 Bedingte immortalisierung von zellen ATE297987T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99307405 1999-09-17
US09/663,537 US6399384B1 (en) 1999-09-17 2000-09-15 Conditional immortalization of cells
PCT/GB2000/003588 WO2001021790A1 (en) 1999-09-17 2000-09-18 Conditional immortalisation of cells

Publications (1)

Publication Number Publication Date
ATE297987T1 true ATE297987T1 (de) 2005-07-15

Family

ID=26153574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00960846T ATE297987T1 (de) 1999-09-17 2000-09-18 Bedingte immortalisierung von zellen

Country Status (11)

Country Link
US (1) US6399384B1 (de)
EP (1) EP1212420B1 (de)
JP (1) JP2003510046A (de)
CN (1) CN1373804A (de)
AT (1) ATE297987T1 (de)
AU (1) AU757816B2 (de)
CA (1) CA2383253A1 (de)
DE (1) DE60020855T2 (de)
ES (1) ES2241652T3 (de)
IL (1) IL148008A0 (de)
WO (1) WO2001021790A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518606D0 (en) * 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
GB9907243D0 (en) * 1999-03-29 1999-05-26 Reneuron Ltd Therapy
GB0005856D0 (en) * 2000-03-10 2000-05-03 Reneuron Ltd Genetic constructs
DE10019195B4 (de) * 2000-04-17 2006-03-09 Heart Biosystems Gmbh Reversible Immortalisierung
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) * 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
EP1207196A1 (de) * 2000-10-27 2002-05-22 Societe Des Produits Nestle S.A. Immortalisierte pre-osteoblasten und verfahren zur deren herstellung
EP1418932A4 (de) * 2001-07-18 2006-03-15 Univ Texas Antiangiogener zustand bei mäusen und menschen mit retinaler photorezeptor-degeneration
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
GB0125773D0 (en) * 2001-10-26 2001-12-19 Reneuron Ltd Constructs
EP1447443A4 (de) * 2001-10-31 2006-06-07 Renomedix Inst Inc Immortalisierte mesenchymzellen und ihre verwendung
ES2353665T3 (es) * 2002-03-15 2011-03-03 Duke University Ingeniería tisular.
BRPI0409383A (pt) * 2003-04-14 2006-04-18 Univ Texas métodos para produção livre de hibridoma ex vivo de anticorpos policlonais e monoclonais e geração de populações de célula imortalizada
WO2005026201A1 (en) * 2003-09-12 2005-03-24 Reneuron Limited Immortalisation of mammalian cells and therapeutic applications of said cells
US20050193432A1 (en) * 2003-11-18 2005-09-01 Whitehead Institute For Biomedical Research Xenograft model of functional normal and malignant human breast tissues in rodents and methods thereof
DE602005002430T2 (de) 2004-09-30 2008-06-19 Reneuron Ltd., Guildford Zelllinie
US20090298095A1 (en) 2005-04-15 2009-12-03 The John Hopkins University Immortalization of cells including neuronal cells
BRPI0619908A2 (pt) * 2005-12-16 2011-10-25 Ribovax Biotechnologies Sa método para imortalização de uma população de células, população de células, população de células oligoclonal ou monoclonal, cultura celular, sobrenadante de uma cultura celular, biclioteca de dnas, uso de uma população de células, cultura celular, sobrenadante ou biblioteca de dnas, kit para identificar e produzir um anticorpo monoclonal, método para produzir uma cultura celular, e método para produzir um anticorpo monoclonal
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method
EP2380905A1 (de) 2010-04-19 2011-10-26 Thrombotargets Europe, S.L. Phospholipidangereicherte Vesikel mit Gewebefaktor mit blutstillenden Aktivitäten sowie Verwendungen davon
CN105176913A (zh) * 2015-09-23 2015-12-23 扬州大学 一种奶牛乳腺上皮细胞永生化方法
WO2020131717A1 (en) * 2018-12-16 2020-06-25 Figene, Llc Therapeutic uses of gene edited fibroblasts
GB202005494D0 (en) 2020-04-15 2020-05-27 Reneuron Ltd Induced pluripotent cell comprising a contollable transgene for conditional immortalisation
CN116355834A (zh) * 2023-03-29 2023-06-30 复旦大学附属中山医院 一种小鼠肝星状细胞的永生化制备试剂、试剂盒及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270191A (en) * 1988-04-12 1993-12-14 Massachusetts Institute Of Technology Method for manipulation of the cell types of eukaryotes
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
EP0799315A2 (de) 1994-12-19 1997-10-08 Cold Spring Harbor Laboratory Telomerase protein-komponente
GB9518606D0 (en) 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
IL129222A0 (en) * 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
WO1998037181A2 (en) 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein

Also Published As

Publication number Publication date
JP2003510046A (ja) 2003-03-18
AU7301500A (en) 2001-04-24
CN1373804A (zh) 2002-10-09
ES2241652T3 (es) 2005-11-01
EP1212420B1 (de) 2005-06-15
WO2001021790A1 (en) 2001-03-29
DE60020855T2 (de) 2006-05-04
AU757816B2 (en) 2003-03-06
US6399384B1 (en) 2002-06-04
EP1212420A1 (de) 2002-06-12
CA2383253A1 (en) 2001-03-29
IL148008A0 (en) 2002-09-12
DE60020855D1 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
DE60020855D1 (de) Bedingte immortalisierung von zellen
DK1280898T3 (da) Modificerede ES-celler og ES-cellespecifikt gen
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
ATE342275T1 (de) Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
IL181437A0 (en) Medium and culture of embryonic stem cells
DE69725587D1 (de) Verwendung von wnt polypeptiden
DK1474507T3 (da) Fremgangsmåder og materialer til produktion af organiske produkter i celler af Candida arter
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
EP1180932A4 (de) Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
DK1137808T3 (da) Fremgangsmåde til fremstilling af rekombinante celler
ATE348876T1 (de) Verfahren zur vermehrung von natürlichen killerzellen
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
ATE326537T1 (de) Schnell erzeugung von stabilen säugertier- zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
GB9825096D0 (en) Cells,culture methods and their uses
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
FR2716205B1 (fr) Récepteur galanine, acides nucléiques, cellules transformées et utilisations.
AR020208A1 (es) Construcciones de adn
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
BR0014489B1 (pt) processo de produÇço de adenovÍrus, e, kit.
FI972909A0 (fi) Oekad produktion av avsoendrade proteiner genom rekombinatjaestceller
WO2000053759A8 (en) Expression of human alpha-fetoprotein in mammalian cells
ATE283918T1 (de) Tumorsuppressorgen
DE69939825D1 (de) Genetische transduktion von hämatopoietische vorläuferzellen
DE10083676T1 (de) Rekombinantes Enzym mit ausgezeichneter D-Aminosäureoxidaseaktivität sowie dessen Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1212420

Country of ref document: EP

REN Ceased due to non-payment of the annual fee